Chronic prostatitis symptoms stabilize over time

Boston-Perhaps offering a measure of reassurance to prostatitis patientsand their urologists, data from a prospective study suggest that the symptomsof chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) typicallyimprove or remain stable over time. During a 1-year follow-up of a cohort receiving "usual care"for their symptoms, half the patients had symptom improvement, and morethan one-third reported their symptoms unchanged. Symptoms deterioratedin about 14% of patients.

Related Videos

Related Content

Advertisement

May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

Related Content

Advertisement

May 12th 2025

National Women’s Health Week: Celebrating women shaping the future of urology

Shaya Taghechian, MD Hannah Clarke

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 1st 2025

FDA updates in urology: March 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.